Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2009 December;53(6) > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2009 December;53(6):658-70





A Journal on Nuclear Medicine and Molecular Imaging

A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413




The Quarterly Journal of Nuclear Medicine and Molecular imaging 2009 December;53(6):658-70

language: English

A practical dead time correction method in planar activity quantification for dosimetry during radionuclide therapy

Chiesa C. 1, Negri A. 2, Albertini C. 3, Azzeroni R. 2, Setti E. 4, Mainardi L. 3, Aliberti G. 1, Seregni E. 1, Bombardieri E. 1

1 Unit of Nuclear Medicine, National Cancer Institute IRCCS Milan, Italy;
2 Postgraduate Health Physics School, University of Milan, Milan, Italy;
3 Department of Biomedical Engineering, Milan-Polytechnic, Milan, Italy;
4 Laboratory for Advanced Radiological Analysis (LARA) National Cancer Institute, Milan, Italy


AIM: Gamma camera saturation is the first quantification problem in dosimetric studies following therapeutic administrations of 131I labeled radiopharmaceuticals. A new approach for dead time correction (DTC) is here proposed. It employs planar whole-body (WB) images without the need of standard radionuclide sources or of preliminary phantom calibrations.
METHODS: Step and shoot WB acquisitions of the patient are required. A program was developed to compensate for the image discontinuities (“Continuity DTC method”) between two adjacent static fields of view (FOVs) caused by different dead time count losses. For its validation, authors used two 99mTc 6 GBq phantom scans after administration of six patients with 131I labeled agents with different statistics and ten clinical scans taken between 16 h and 48 h after administration of 131I labeled agents, whose activity ranged from 4 to 10 GBq. The deviation from true decay corrected counts on phantoms and the constancy of monitor point-source counts in different patients’ FOVs (root mean square error and maximum deviation) served as figures of merit. The accuracy of absorbed dose calculation was also estimated by comparison with the standard source correction method, computing the area under the time activity curve (AUC) of six lesions.
RESULTS: With respect to the true phantom counts, corrected images gave excellent results, giving a 6% maximum deviation. For what concerns the other figures of merit, continuity DTC reduced the average root mean square error from 36% to 2% and the mean maximum deviation from 50% to 2%, on phantom, while from 51% to 32/28% (absence/presence of triple energy window scatter correction) and from 72% to 21/14% on patients. Mean compensation of AUC gave a correction of +56% with our method, while +78% with standard source method.
CONCLUSIONS: The “Continuity DTC method” is a useful tool in dosimetry during nuclear medicine treatment, showing good accuracy. Moreover, since it does not require the use of any source, it provides with several advantages in terms of practicability and applicability, with respect to the standard source method and to methods based on the count rate characteristic curve.

top of page

Publication History

Cite this article as

Corresponding author e-mail